Guardian Technologies' Advances Signature Mapping(TM) Initiatives.
Based on promising internal research and development results, Guardian commenced a broader survey that was designed to evaluate and validate the applicability of Signature Mapping[TM] to the medical imaging applications. A series of broad pilot studies involving multiple modalities and multiple diseases were undertaken through a collaborative effort with the Image Processing and Informatics Laboratory (IPI) at the University of Southern California. IPI provided clinical cases including radiographs with confirmed diagnoses, as well as medical imaging informatics expertise. Clinical study areas and imaging modalities were chosen based upon their ability to provide Guardian broad and deep insight into the capabilities of its core technologies.
The initial pilot study chosen was multiple sclerosis (MS), a disease that has been diagnosed in over 400,000 Americans. Healthcare experts believe that over one million people currently live with multiple sclerosis today in the U.S. MS patients undergo multiple MRI scans that require the radiologist to quantify and report any changes to MS lesions over multiple studies and time. This evaluation process is a time-consuming and imprecise activity when performed without the benefits of an automated detection technology such as Signature Mapping[TM].
Results of the MS study found that Signature Mapping[TM] algorithms are capable of accurately detecting lesions and, more importantly, provide accurate measurements of size and overall lesion volumes. Compared to clinical observers, Signature Mapping[TM] proved to be a more sensitive tool for detecting lesions that were considered marginal or undetectable and provided extremely accurate measurements, while reducing the radiologist analysis time to just seconds.
Normal pressure hydrocephalus was also analyzed by IPI. In the normal course of aging the adult brain begins to shrink as a result the internal ventricles which contain cerebral spinal fluid begin to enlarge. Enlargement of the ventricles is also associated with numerous anomalies including obstructing tumors. The challenge faced by the radiologist is to determine whether the pressure changes in the ventricles are caused by the normal course of aging or as a result of an anomaly. Signature Mapping[TM] technologies detected and quantified the ventricles and cranial spinal fluid visualized from the MRI images. IPI reviewed the results of utilizing Signature Mapping[TM] and determined the effects to be impressive by demonstrating its ability to detect cerebral spinal fluid, provide a methodology for segmenting the ventricles and determining and quantifying ventricular size and volume.
Acute intracranial hemorrhage was the third area of application in the brain for Signature Mapping[TM]. This area is of clinical interest due to the large number of intracranial bleeds occurring either due to disease, such as stroke, or from traumatic head injury. There are over 1.5 million traumatic brain injuries in the United States each year. The goal was to develop a Signature Mapping[TM] technology for accurately segmenting and detecting intracranial bleeding using axial Computer Tomography (CT) slices. Cases were categorized into three groups; gross identifiable bleeding, subtle small subdural bleeds and extremely small subdural bleeds which could be confused with CT bone hardening artifacts. Signature Mapping[TM] demonstrated in all cases to be an accurate and sensitive tool for the detection of acute intracranial bleeds. It also demonstrated an ability to differentiate between small intracranial bleeds such as less than 5% subdural hematomas and difficult to discern bone hardening artifacts typical in most CT scans.
The use of Signature Mapping[TM] to monitor tuberculosis (TB) changes over treated time using radiographic chest x-rays was also studied. Tuberculosis is a serious world health problem; the World Health Organization estimates that over 2 billion people or one third of the world population has or will contract tuberculosis. Tuberculosis is an immune deficiency disease and is a complication of HIV disease. Tuberculosis is a leading cause of death outside the United States afflicting millions of people in Africa and Eastern Asia. A Signature Mapping[TM] technology was developed to detect lung volume area, quantifying normal lung volume from diseased lung volume and quantitatively report changes in lung volume through drug treatment progress. Signature Mapping[TM] proved to be successful in detecting lung area, quantifying normal lung volumes, and reporting lung volume changes over time during drug treatment therapies. It demonstrated itself to be an excellent tool to aid in quantification and tracking of TB therapy.
The last and most difficult area that was evaluated was breast imaging. Two specific challenges are in the areas of image clarification and the clinical interpretation of dense breast digital x-ray examinations. Clinicians at USC indicated that as high as 50% of their dense breast tumors could be palpated, but not clearly seen or detected on x-rays. Typically these dense breast areas obscure the visualization of anomalies and potential tumors. Signature Mapping[TM] technology was used to clarify difficult to visualize areas of the breast and to provide improved visualization and detection of tumor areas and edges. Preliminary results suggest a likely opportunity for early detection and mapping of tumors and tumor growth over time. Microcalcifications were easily visualized and demonstrated unique signature responses. Results were extremely encouraging and further clinical study is required.
Overall Guardian is extremely excited by its ability to add clinical value to difficult imaging problems in diagnostic radiology. Guardian was able to demonstrate its ability to easily transfer its Signature Mapping[TM] technologies to a new imaging industry application. The Signature Mapping[TM] technologies proved to be an effective tool for detection, segmentation, clarification, quantification and visualization for specifically targeted diseases or anatomical structures. The technology shows broad modality and clinical adaptation for deployment in a wide variety of clinical diagnostic and therapeutic applications.
About Guardian Technologies International, Inc.
Guardian Technologies International, Inc. (OTCBB:GDTI) employs high-performance imaging technologies and advanced analytics to create integrated information management products and services. Guardian's technologies are focused on two primary markets: Homeland Defense and Healthcare Solutions. For additional information, visit www.guardiantechintl.com.
This news release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements in this document and those made from time to time by Guardian through its senior management are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current views with respect to the future events or financial performance discussed in this release, based on management's beliefs and assumptions and information currently available. When used, the words "believe", "anticipate", "estimate", "project", "should", "expect", "plan", "assume" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Forward-looking statements concerning future plans or results are necessarily only estimates and actual results could differ materially from expectations. Certain factors that could cause or contribute to such differences include, among other things, in particular, the size and timing of contract awards, performance on contracts, performance of acquired companies, availability and cost of key components, unanticipated results from audits of the financial results of the Company and acquired companies, changing interpretations of generally accepted accounting principles, outcomes of government reviews, developments with respect to litigation to which we are a party, potential fluctuations in quarterly results, dependence on large contracts and a limited number of customers, lengthy sales and implementation cycles, market acceptance of new or enhanced products and services, proprietary technology and changing competitive conditions, system performance, management of growth, dependence on key personnel, ability to obtain project financing, general economic and political conditions and other factors affecting spending by customers, the unpredictable nature of working with government agencies and other risks, uncertainties and factors including those described from time to time in Guardian's filings with the Securities and Exchange Commission, including without limitation, Guardian's Form 10-K for the year ended December 31, 2005 and its quarterly reports on Form 10-Q. Guardian expressly disclaims any obligation to update any forward-looking statements.
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 15, 2007|
|Previous Article:||Semiconductor Engineering and Failure Analysis Tool from SELA Enters Production Phase; Manufacturing Operations Expand to Accommodate Demand for...|
|Next Article:||Regeneron to Present at Lehman Brothers 10th Annual Global Healthcare Conference.|